If you have been reading about lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
== Formal scientific review == In 2006, the U.S. National Academy of Sciences released the report of a study of molecular manufacturing (not molecular assemblers per se) as part of a longer report, A Matter of Size: Triennial Review of the National Nanotechnology Initiative The study committee reviewed the technical content of Nanosystems, and in its conclusion states that no current theoretical analysis can be considered definitive regarding several questions of potential system performance, and that optimal paths for implementing high-performance systems cannot be predicted with confidence. It recommends funding for experimental research to produce experimental demonstrations in this area: "Although theoretical calculations can be made today, the eventually attainable range of chemical reaction cycles, error rates, speed of operation, and thermodynamic efficiencies of such bottom-up manufacturing systems cannot be reliably predicted at this time. Thus, the eventually attainable perfection and complexity of manufactured products, while they can be calculated in theory, cannot be predicted with confidence. Finally, the optimum research paths that might lead to systems which greatly exceed the thermodynamic efficiencies and other capabilities of biological systems cannot be reliably predicted at this time. Research funding that is based on the ability of investigators to produce experimental demonstrations that link to abstract models and guide long-term vision is most appropriate to achieve this goal."
In biology, matrix (pl.: matrices) is the material (or tissue) in between cells within a eukaryotic organism. The structure of connective tissues is an extracellular matrix. Fingernails and toenails grow from matrices. It is found in various connective tissues. It serves as a jelly-like structure instead of cytoplasm in connective tissue.
== Other animals == Bowed tendon is a term for form of tendinitis (inflammation) and tendinosis (degeneration) most commonly seen in the superficial digital flexor tendon in the front leg of horses. Mesenchymal stem cells, derived from a horse's bone marrow or fat, can be used for tendon repair in horses.
With increased concerns about nuclear waste, breeding fuel cycles came under renewed interest as they can reduce actinide wastes, particularly plutonium and minor actinides such as neptunium, americium and curium. Breeder reactors are designed to fission the actinide wastes as fuel and thus convert them to more fission products. For unreprocessed uranium-oxide spent nuclear fuel, Bodansky's 2006 review described a rapid initial decrease in radioactivity as short-lived fission products decay, followed by a more gradual decrease as actinides decay. Today's commercial light-water reactors do breed some new fissile material, mostly in the form of plutonium. Because commercial reactors were never designed as breeders, they do not convert enough uranium-238 into plutonium to replace the uranium-235 consumed. Nonetheless, at least one-third of the power produced by commercial nuclear reactors comes from fission of plutonium generated within the fuel. Even with this level of plutonium consumption, light water reactors consume only part of the plutonium and minor actinides they produce, and nonfissile isotopes of plutonium build up, along with significant quantities of other minor actinides. Since breeder reactors on a closed fuel cycle would use nearly all of the isotopes of these actinides fed into them as fuel, their fuel requirements would be reduced by a factor of about 100. Waste volume alone does not determine disposal requirements. A 2023 DOE assessment identified radionuclide inventory, heat output, chemical and physical properties, and packaging as relevant factors.
== External links == Weighting cancer drugs to make them hit tumors harder at PhysOrg.com Designing Better Cancer Drugs Insight into Carrier Molecules' Functionality which may yield Safer Cancer Treatments at MIT magazine TechnologyReview.com
Sources: en.wikipedia.org
anti-fascists persons crucial for industries those married to ethnic Czechs It is estimated that between 700,000 and 800,000 Germans were affected by "wild" expulsions between May and August 1945. The expulsions were encouraged by Czechoslovak politicians and were generally carried out by the order of local authorities, mostly by groups of armed volunteers. However, in some cases it was initiated or pursued by assistance of the regular army. The expulsion according to the Potsdam Conference proceeded from 25 January 1946 until October of that year. An estimated 1.6 million ethnic Germans were deported to the American zone of what would become West Germany. An estimated 800,000 were deported to the Soviet zone (in what would become East Germany). Several thousand died violently during the expulsion and many more died from hunger and illness as a consequence. These casualties include violent deaths and suicides, deaths in internment camps and natural causes. The joint Czech-German commission of historians stated in 1996 the following numbers: The deaths caused by violence and abnormal living conditions amount to approximately 10,000 persons killed. Another 5,000–6,000 people died of unspecified reasons related to expulsion making the total number of victims of the expulsion 15,000–16,000 (this excludes suicides, which make another approximately 3,400 cases). Approximately 225,000 Germans remained in Czechoslovakia, of whom 50,000 emigrated or were expelled soon after.
== Other aspects and examples == In the CCS system, carbon chain lengths are denoted by celestial stems (甲 jiǎ, 乙 yǐ, 丙 bǐng, 丁 dīng, 戊 wù, 己 jǐ, 庚 gēng, 辛 xīn, 壬 rén, 癸 guǐ), characters used since the Shang dynasty (16th–11th centuries BCE) for naming days (and later, to name years). For example, hexane is 己烷 jǐwán, since 己 jǐ is the sixth celestial stem. Longer carbon chains are specified by number followed by '碳' tàn 'carbon'. For example, 1-hexadecene is 1-十六碳烯 (read as [1, yī] [-, wèi] [十六, shíliù, '16'] [碳, tàn] [烯, xī]), where the hyphen is read as 位 (wèi, 'position'). For a more complex example, consider 3-buten-1-ol. Its Chinese name is 3-丁烯-1-醇 (read as [3, sān] [-, wèi] [丁, dīng] [烯, xī] [1, yī] [-, wèi] [醇, chún]). The descriptors for degree of substitution, primary, secondary, tertiary, and quaternary, are translated as 伯 (bó), 仲 (zhòng), 叔 (shū), 季 (jì), which refer to the first, second, third, and fourth male siblings in a family. For instance, tert-butyllithium is translated as 叔丁基锂 ([叔, shū, 'tert'], [丁, dīng, 'but-'], [基, jī, 'yl'], [锂, lǐ, 'lithium']). Other commonly used isomeric descriptors normal-, iso-, and neo- are translated as 正 (zhèng, 'proper'), 异 (yì, 'different'), and 新 (xīn, 'new'), respectively. The numerical prefix bis- is translated as 双 (shuāng, 'double'), while larger multiplicities are simply given by the Chinese word for the number (e.g., 四 (sì, 'four') for tetrakis-). For example, tetrakis(triphenylphosphine)palladium is rendered 四(三苯基膦)钯, in which 三苯基膦 is triphenylphosphine and 钯 is palladium.
Cytotoxic T cells (also known as Tc, killer T cell, or cytotoxic T-lymphocyte (CTL)) express CD8 co-receptors and are a population of T cells that are specialized for inducing programmed cell death of other cells. Cytotoxic T cells regularly patrol all body cells to maintain the organismal homeostasis. Whenever they encounter signs of disease, caused for example by the presence of viruses or intracellular bacteria or a transformed tumor cell, they initiate processes to destroy the potentially harmful cell. All nucleated cells in the body (along with platelets) display class I major histocompatibility complex (MHC-I molecules). Antigens generated endogenously within these cells are bound to MHC-I molecules and presented on the cell surface. This antigen presentation pathway enables the immune system to detect transformed or infected cells displaying peptides from modified-self (mutated) or foreign proteins. In the presentation process, these proteins are mainly degraded into small peptides by cytosolic proteases in the proteasome, but there are also other cytoplasmic proteolytic pathways. Then, peptides are distributed to the endoplasmic reticulum (ER) via the action of heat shock proteins and the transporter associated with antigen processing (TAP) which translocates the cytosolic peptides into the ER lumen in an ATP-dependent transport mechanism. There are several ER chaperones involved in MHC-I assembly, such as calnexin, calreticulin, Erp57, protein disulfide isomerase (PDI), and tapasin.
The use of C–H functionalization in the synthesis of lithospheric acid exemplifies the site- and stereoselective capabilities of using MPAA ligands in these reactions. As the penultimate step, the intermolecular C–H olefination introduces almost double the complexity into the compound enabling the highly convergent synthesis.
Sources: en.wikipedia.org
== Structure == Three dimensional structure of none of the members of Angiopoietin like proteins (ANGPTLs) is available up until now. However, the structure of ANGPTL8 was predicted by homology modeling and is also reported in literature. It consists of alpha helices and its sequence show high similarity with the coiled-coil domains of ANGPTL3 and ANGPTL4.
In 1957, Chien-Shiung Wu et al. discovered that β-decay violated parity, implying nature (the weak force) sees handedness. In the Wu experiment, researchers aligned 60Co nuclei by cooling the source to low temperatures in a magnetic field. Wu's observation was that more β-rays were emitted in the opposite direction to the nuclear spin. This asymmetry violates parity conservation.
=== History === Sulfonylureas were discovered in 1942, by the chemist Marcel Janbon and co-workers in France, who were studying sulfonamide antibiotics and discovered that the compound sulfonylurea induced hypoglycemia in animals. Research and development (translational research and commercial application development) for sulfonylureas as pharmaceuticals (as diagnostic and therapeutic agents in prediabetes and diabetes) happened in the 1950s and 1960s, as explored at Tolbutamide § History. Research and development (translational research and commercial application development) for sulfonylureas as herbicides happened in the 1970s and 1980s, as explored for example in a volume of the Sloan Technology Series focusing on the sociotechnological aspects of agriculture (Canine 1995); the DuPont Experimental Station led this development.
== Pharmacology == DL-threo-beta-benzyloxyaspartate (TBOA) is an inhibitor of the excitatory amino acid transporters. Selective inhibitors for EAAT1 have recently been discovered based on 25 combinations of substitutions at the 4 and 7 positions of 2-amino-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitril.
== Diagonals == If e, f, g and h are the tangent lengths from A, B, C and D respectively to the points where the incircle is tangent to the sides of a tangential quadrilateral ABCD, then the lengths of the diagonals p = AC and q = BD are
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.